We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novo awaits green light for diabetes drug.
- Authors
May, Mike
- Abstract
This article reports that Novo Nordisk awaits a decision from the U.S. Food & Drug Administration (FDA) on its anti-diabetic drug Victoza in 2009. An FDA Endocrinologic and Metabolic Drugs Advisory Committee conducted a discussion which suggests that C-cell thyroid cancer could be a potential safety concern associated with the drug. The Danish company seeks the approval to secure a share in the type 2 diabetes market. The company conducted a number of studies to examine the efficacy and safety of the drug.
- Subjects
UNITED States; DRUG approval; UNITED States. Food &; Drug Administration; NOVO Nordisk A/S; THYROID cancer; DRUG efficacy
- Publication
Nature Biotechnology, 2009, Vol 27, Issue 8, p682
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0809-682c